Literature DB >> 9317045

Ablation of interleukin-12 exacerbates Lyme arthritis in SCID mice.

J Anguita1, S Samanta, S W Barthold, E Fikrig.   

Abstract

The administration of interleukin-12 (IL-12) antibodies to Borrelia burgdorferi-infected C3H/HeN-scid mice increased the severity of acute Lyme arthritis. These results contrasted with the reduction of Lyme arthritis by IL-12 antibodies in immunocompetent animals. These data suggest that downregulation of innate immunity in SCID mice in the absence of B- and T-cell responses leads to an exacerbation of joint inflammation.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9317045      PMCID： PMC175621          DOI： 10.1128/iai.65.10.4334-4336.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  24 in total

1.  Protection of mice against the Lyme disease agent by immunizing with recombinant OspA.

Authors:  E Fikrig; S W Barthold; F S Kantor; R A Flavell
Journal:  Science       Date:  1990-10-26       Impact factor: 47.728

2.  Kinetics of Borrelia burgdorferi dissemination and evolution of disease after intradermal inoculation of mice.

Authors:  S W Barthold; D H Persing; A L Armstrong; R A Peeples
Journal:  Am J Pathol       Date:  1991-08       Impact factor: 4.307

3.  Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection.

Authors:  L Soong; J C Xu; I S Grewal; P Kima; J Sun; B J Longley; N H Ruddle; D McMahon-Pratt; R A Flavell
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

4.  CD40 ligand is required for protective cell-mediated immunity to Leishmania major.

Authors:  K A Campbell; P J Ovendale; M K Kennedy; W C Fanslow; S G Reed; C R Maliszewski
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

5.  Lyme borreliosis in the severe combined immunodeficiency (scid) mouse manifests predominantly in the joints, heart, and liver.

Authors:  U E Schaible; S Gay; C Museteanu; M D Kramer; G Zimmer; K Eichmann; U Museteanu; M M Simon
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

6.  Lyme borreliosis in selected strains and ages of laboratory mice.

Authors:  S W Barthold; D S Beck; G M Hansen; G A Terwilliger; K D Moody
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

7.  Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice.

Authors:  E Fikrig; S W Barthold; N Marcantonio; K Deponte; F S Kantor; R A Flavell
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

Review 8.  Immunity to Lyme disease: protection, pathology and persistence.

Authors:  K P Seiler; J J Weis
Journal:  Curr Opin Immunol       Date:  1996-08       Impact factor: 7.486

9.  Effect of anti-interleukin 12 treatment on murine lyme borreliosis.

Authors:  J Anguita; D H Persing; M Rincon; S W Barthold; E Fikrig
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

10.  Isolation and cultivation of Lyme disease spirochetes.

Authors:  A G Barbour
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug
View more
  11 in total

Review 1.  Lyme arthritis: current concepts and a change in paradigm.

Authors:  Dean T Nardelli; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

2.  Interleukin-4 (IL-4) and IL-13 signaling pathways do not regulate Borrelia burgdorferi-induced arthritis in mice: IgG1 is not required for host control of tissue spirochetes.

Authors:  M R Potter; N Noben-Trauth; J H Weis; C Teuscher; J J Weis
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Innate immune responses in Lyme borreliosis: enhanced tumour necrosis factor-alpha and interleukin-12 in asymptomatic individuals in response to live spirochetes.

Authors:  J Sjöwall; A Carlsson; O Vaarala; S Bergström; J Ernerudh; P Forsberg; C Ekerfelt
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

4.  Dual role of interleukin-10 in murine Lyme disease: regulation of arthritis severity and host defense.

Authors:  J P Brown; J F Zachary; C Teuscher; J J Weis; R M Wooten
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

5.  Genetic control of experimental lyme arthritis in the absence of specific immunity.

Authors:  C R Brown; S L Reiner
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

6.  Cyclooxygenase 2 activity modulates the severity of murine Lyme arthritis.

Authors:  Juan Anguita; Swapna Samanta; Shobana K Ananthanarayanan; Beatriz Revilla; Gregory P Geba; Stephen W Barthold; Erol Fikrig
Journal:  FEMS Immunol Med Microbiol       Date:  2002-11-15

7.  Role of osteopontin in murine Lyme arthritis and host defense against Borrelia burgdorferi.

Authors:  Melissa R Potter; Susan R Rittling; David T Denhardt; Randall J Roper; John H Weis; Cory Teuscher; Janis J Weis
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

8.  Gamma interferon is not required for arthritis resistance in the murine Lyme disease model.

Authors:  L Glickstein; M Edelstein; J Z Dong
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

9.  Acquired resistance but not innate resistance to Mycobacterium bovis bacillus Calmette-Guérin is compromised by interleukin-12 ablation.

Authors:  L Thompson-Snipes; E Skamene; D Radzioch
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

10.  Activation of natural killer cells in arthritis-susceptible but not arthritis-resistant mouse strains following Borrelia burgdorferi infection.

Authors:  C R Brown; S L Reiner
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.